Sign in with Google. Opens in new tab
bearish
Dr Lal PathLabs (DLPL IN): Losing Path Amid Competition; Non-COVID Growth Underwhelming
546 Views30 Mar 2023 10:49
SUMMARY
- Dr Lal PathLabs Ltd (DLPL IN) reported 2% and 8% revenue and net profit decline in Q3FY23, respectively. Q3 results were dragged by an 80% YoY decline in COVID-19 revenue.
- While non-COVID revenue increased 9% YoY to INR4.78 billion, it declined 7% QoQ. In fact, Q3FY23 non-COVID revenue was the lowest over the last three quarters.
- Although diagnostics is a big and attractive market opportunity in India, the sector is overcrowded, leading to heated price competition and declining realization per test.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Sichuan Kelun Biotech (6990 HK): Price Surge & Global Index Inclusion
- NIFTY50 Index Rebalance Preview: Forecast Changes, Impact, Positioning
- Anthem Biosciences IPO: Lists Today; Index Inclusion Timing
- Reece (REH AU): Positioning Increases as Global Index Deletion Nears
- Crime Scene Investigation: How Seven&I (3382-JP) Murdered the ACT (ATD-CA) Deal
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- APAC Healthcare Weekly (Oct 6)-Strong Yen Impact, Sigma's Remedial Measures, Mesoblast's Fund Raise05 Oct 2024
- Dr Lal PathLabs Ltd (DLPL IN): Poised for Next Level of Growth Amid Easing Price Competition02 Oct 2024
- Dr Lal PathLabs (DLPL IN): Strong Trajectory in Non-COVID Business; Positive Industry Outlook11 Jul 2023
- Dr Lal PathLabs (DLPL IN): Q2FY23 Review- Volume Driven Sales Growth; Sequential Margin Improvement10 Nov 2022
- Dr Lal PathLabs Ltd (DLPL IN): Base Business Recovering; Competition Is the Only Headwind26 May 2022
x